ID;post_title;date_depot;numero_depot;numero_depot_international;equipes;co_inventeur_interne;co_inventeurs_externe;ajout_le;post_content 16587;"FLT3 inhibitor for modulating macrophages polarization";20231218;EP23307236.2;;;"A. Jacquel, P. Auberger, M. Loschi, G. Robert, M. Bourgoin, M. Fajolles";;; 11585;"Substituted halo-quinone derivatives, method of preparation and application thereof";;19700067.2;"EP 3 735 408 A1";;;"R. Benhida";; 11584;"Substituted halo-quinone derivatives for use in the treatment of lymphomas and leukemia.";;1970065.6;"EP 3 735 407 A1";;"T. Passeron";"R. Benhida";; 11583;"Novel Substituted Hydrophobic Benzene Sulfonamide Thiazole Compounds";;;EP15306213;;"S. Rocchi";"R. Ballotti M. Plaisant C. Ronco R. Benhida";; 11582;"Novel biguanide compounds and amino-1,2,3-triazine compounds and their applications in oncology";;;"EP 17306912.1";;"S. Rocchi";"R. Benhida C. Ronco O. Grytsai E. Jaune N.Tekaya";; 11581;"Modèle de peau humaine et son utilisation pour évaluer ex vivo les effets dermatologiques, cosmétiques et/ou nutraceutiques de composés";;(#1462836;WO2016097643A1;;"T. Passeron";;; 11580;"Methods and compositions for treating vitiligo";;;WO2019158675A1;;"M. Tulic, T. Passeron";;; 11579;"Methods and compositions for treating hyperpigmentary disorders";;;WO20210079100;;"T. Passeron";"L. Sormani Le Bourhis";; 11578;"Improved NF-kB-inducing kinase (NIK) inhibitors";;21315226.7;;;"T. Passeron";"R. Benhida";; 11577;"Combination of BIP inhibitors and immune checkpoint inhibitors";;"EP 21305912.4";"EP 21305912.4";;"S. Rocchi";"R. Benhida C. Ronco";; 11576;"Biguanide derivatives and their rearrangement products for use in the treatment of cancer";;;"WO 2019/122418A1";;"S. Rocchi";"R. Benhida C. Ronco O. Grytsai E. Jaune N. Tekaya";; 11575;"Benzene sulfonamide thiazole compounds and their use for the treatment of cancers";;EP21306869.5;EP21306869.5;;"S. Rocchi";"R. Benhida C. Ronco";; 11574;"4-amino-quinoline compounds as anti-cancer agents";;;WO/2018/007648;;"T. Passeron";"R. Benhida P. Dao GM De Donatis A. Martin";; 11415;"Methods and pharmaceutical composition for the treatment of infectious diseases";20220208;"EP20305782.3 ";WO2022008597;;"O. Dufies, P. Chaintreuil, J. Courjon, A. Jacquel, P. Auberger, L. Boyer";;; 11414;"Methods and compositions for treatment of SARS-CoV-2 infection";;EP20315109.7;;;"L. Boyer, J. Courjon";;; 11413;"Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders";;EP193005502.7;;;;;; 11006;"METHODS AND COMPOSITIONS FOR TREATING MELANOMA: Use of anti-fibrotic drugs to enhance targeted therapies in melanoma.";20220316;EP21305325.9;PCT/EP2022/056776;;"S. Tartare-Deckert, M. Deckert";"S. Diazzi, B. Mari";; 10380;"Methods for diagnosis and monitoring form of coronavirus infection";;20/10/2020;;"Team 02";"A. Jacquel, P. Auberger, L. Boyer";;; 10378;"Methods and compositions for treating myeloid neoplasias";20140429;;WO2015165975;"Team 02";"A. Jacquel, P. Auberger";"Nathalie Droin; Eric Solary";; 10376;"Methods and compositions for treatment of sars-cov-2 infection";20200403;;WO2021198511;"Team 02";"L. Boyer, P. Auberger, J. Courjon, C. Pomares, V. Giordanengo, O. Visvikis, C. Loubatier, O. Dufies, C. Torre, A. Doye, P. Munro, R. Lotte, A. Jacquel, A. Robert";"Stoyan Ivanov; Sebastien Vitale; ";; 10373;"Methods and pharmaceutical composition for the treatment of infectious diseases";20220208;"EP20305782.3 ";WO2022008597;"Team 02";"O. Dufies, P. Chaintreuil, J. Courjon, A. Jacquel, P. Auberger, L. Boyer";;; 9245;"METHODS FOR DETERMINING WHETHER A SUBJECT WAS ADMINISTERED WITH AN ACTIVATOR OF THE PPAR BETA/DELTA PATHWAY";20170811;WO/2018/029336;PCT/EP2017/070419;"Team 09";"J. Neels, J. Murdaca";"ROUSSEAU Anne-Sophie, SIBILLE Brigitte, MOTHE-SATNEY, Isabelle, GRIMALDI Paul";; 8815;"Methods and pharmaceutical compositions for the treatment of cardiometabolic diseases";20200124;;BIO19473;"Team 13";;;; 8814;"UPR targeting for the treatment of NASH and CHC";;;MBIO17600;"Team 13";;;; 8813;"Diagnosis of myeloproliferative neoplasma";;;EB19024;"Team 13";;;; 8812;"Methods for predicting or treating myelopoiesis-driven cardiometabolic diseases";20200212;;IT#1000331966;"Team 13";;;; 8784;"methods and compositions for treating liver diseases";20190215;16/970.031;PCT/EP2019/053807;;"B. Bailly-Maitre, P. GUAL, A. TRAN";;; 8775;"VDAC1-S as a cell marker (PR 92989)";;"WO 2012156928 A1";"WO 2012156928 A1";;"N. Mazure";;; 8773;"METHODS AND COMPOSITIONS FOR SELECTING A CANCER TREATMENT IN A SUBJECT SUFFERING FROM CANCER";;"N°19305762.7 ";;"Team 05";"N. Mazure";"Lucilla Fabbri Maeva Dufies";; 8771;"METHODS AND COMPOSITIONS FOR SELECTING A CANCER TREATMENT IN A SUBJECT SUFFERING FROM CANCER";;"N° 19 305 179.4 ";;"Team 05";"N. Mazure";"Lucilla Fabbri Maeva Dufies";; 8197;"TPL2 kinase inhibitors for preventing or treating diabetes and for promoting beta-cell survival";;PCT/EP2013/072314;WO2014064215;"Team 07";"JF. Tanti";"S Dalle; E Varin; A Wojtusciszyn";; 7457;"Targeting leukemia metabolism or essential amino acid uptake shows anti-tumoral activity in PTEN-deficient T cell mouse lymphomas and T-ALL/T-LL human cells.";20140301;N°61/947,325;"US.Provisional Application N°61/947,325";"Team 04";"JF. PEYRON";;; 7453;"Methods for monitoring the response to treatment and for treating colorectal cancer";20120210;"PCT/EP2012/052345 ";;"Team 04";"JF. PEYRON";;; 7430;"METHODS AND COMPOSITIONS COMBINING AT LEAST ONE PATTERN RECOGNITION RECEPTOR (PRR) AGONIST WITH AN ANTI-IL10 RECEPTOR ANTIBODY";20180104;WO/2018/060514;"PCT/EP2017/074949 ";"Team 08";"C. LUCI";"ANJUERE Fabienne, HACINI-RACHINEL Feriel, VIAL Emmanuel";; 7428;"METHODS AND COMPOSITIONS FOR TREATING PRECANCEROUS LESIONS OR CANCER COMPRISING TLR/TLR OR TLR/CLR AGONISTS";20180405;WO/2018/060514;PCT/EP2017/074949;"Team 08";"C. LUCI";"ANJUERE Fabienne, HACINI-RACHINEL Feriel, VIAL Emmanuel ";; 7059;"PLA2R1 as anti-tumoral and as biomarker for the detection of cancer.";20120706;PCT/EP2012/063272;WO/2013/007640;;"C. Girard";"Bernard D, Augert A, Lambeau G, Vindrieux D";; 7017;"Method and compositions for treating liver diseases";20190822;WO/2019/158689;PCT/EP2019/053807;;"B. Bailly-Maitre, P. GUAL, A. TRAN";;; 5845;"A METHOD FOR PREDICTING THE RESPONSIVENESS OF A PATIENT TO A TREATMENT WITH mTOR INHBITORS";;;EP17305294.5;"Team 03";"J. Chiche, JE. Ricci";"Catherine Thieblemont";; 5843;"METHODS FOR DETERMINING THE METABOLIC STATUS OF LYMPHOMAS";;;WO2017/055484;"Team 03";"J. Chiche, JE. Ricci";"Catherine Thieblemont";; 5841;"A METHOD FOR PREDICTING THE RESPONSIVENESS A PATIENT TO A TREATMENT WITH AN ANTI-CD20 ANTIBODY";;;WO2015/132163;"Team 03";"J. Chiche, JE. Ricci";"catherine Thieblemont ";; 4452;"METHODS AND COMPOSITIONS FOR TREATING MELANOMA: PSMD14 as a new therapeutic target in melanoma.";20210115;PCT/EP2021/050815;"WO 2021/144426";;"M. Deckert, M. Ohanna, S. Tartare-Deckert";"P. Biber";; 4449;"METHODS AND COMPOSITIONS FOR TREATING MELANOMA: PTX3: a novel biomarker and therapeutic target for metastatic melanoma.";20200429;PCT/EP2020/061869;"WO 2020/221796";"Team 11";"S. Tartare-Deckert, M. Deckert";"M. Rathore, M. Tichet";; 4447;"COMPOSITIONS FOR TREATING MELANOMA: A novel combination therapy to overcome matrix-mediated drug resistance in melanoma.";20190619;PCT/EP2019/066224;"WO 2019/243431";"Team 11";"S. Tartare-Deckert, M. Deckert";"I. Berestjuk";; 4437;"METHODS AND COMPOSITIONS FOR TREATING MELANOMA: USP14 as a new therapeutic target in melanoma";20180323;PCT/EP2018/057406;"WO 2018/172508";"Team 11";"M. Deckert, S. Tartare-Deckert";"A. Mallavialle, R. Didier";; 3901;"Use of llt1 and/or cd161 for modulatting the activity of cells of the immune system";20040716;EP04/291913A;WO/2006/010603;;"V. PROD'HOMME";"V. BRAUD, H. JOSSO-ALDEMIR";;